Loading clinical trials...
Loading clinical trials...
Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
Conditions
Interventions
VRC-CHKVLP059-00-VP
VRC-PBSPLA043-00-VP
Locations
6
Dominican Republic
Instituto Dermatológico y Cirugía de Piel
Santo Domingo, Dominican Republic
University Hospital of Pointe-à-Pitre
Pointe-à-Pitre, Guadeloupe
Centres GHESKIO
Port-au-Prince, Haiti
Centre Hospitalier Universitaire (CHU), Martinique
Fort-de-France, Martinique
San Juan Hospital, Research Unit
Rio Piedras, Puerto Rico
Puerto Rico Clinical and Translational Research Consortium
San Juan, Puerto Rico
Start Date
November 18, 2015
Primary Completion Date
March 6, 2018
Completion Date
March 6, 2018
Last Updated
October 22, 2020
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions